Protective effects of montelukast on ischemia-reperfusion injury in rat ovaries subjected to torsion and detorsion: biochemical and histopathologic evaluation.
OBJECTIVE
To reveal the effects of montelukast as an antioxidant and tissue protective agent and study the biochemical and histopathologic changes in experimental ischemia and ischemia-reperfusion (I/R) injury in rat ovaries.


METHODS
Experimental study.


METHODS
Experimental surgery laboratory in a university department.


METHODS
Forty-eight rats with experimentally induced ovarian torsion.


METHODS
Group 1: sham; Group 2: ovarian ischemia; Group 3: a 30-hour period of ischemia followed by a 3-hour reperfusion. Groups 4 and 5: rats administered 10 and 20 mg/kg doses of montelukast before a half-hour of ischemia, then ovarian ischemia applied; after a 3-hour period of ischemia, the bilateral ovaries removed. Groups 6 and 7: 3-hour period of ovarian ischemia applied, then 2.5 hours after the ischemia induction, rats given montelukast. Group 8: sham operation and 20 mg/kg of montelukast; at the end of a 3-hour period of ischemia, 3-hours of reperfusion continued.


METHODS
Measurement of ovarian tissue concentrations of superoxide dismutase (SOD), glutathione (GSH), lipid peroxidation (LPO) and myeloperoxidase (MPO) activity; and histopathologic examination of all ovarian rat tissue.


RESULTS
Montelukast treatment normalized changes of LPO and MPO and stimulated an overproduction of endogenous SOD and GSH. The results of the histologic parameters showed that treatment with montelukast in the I/R group of rats ameliorated the development of ischemia and reperfusion tissue injury.


CONCLUSIONS
Montelukast at different doses attenuates ovarian I/R-induced ovary tissue injury in rats.
Oral
Akgun
A
Department of Pediatric Surgery, School of Medicine, Ataturk University, Erzurum, Turkey. ak_oral@hotmail.com
Odabasoglu
Fehmi
F
Halici
Zekai
Z
Keles
Osman Nuri
ON
Unal
Bunyami
B
Coskun
A Kagan
AK
Kilic
Cenk
C
Surer
Ilhami
I
Salman
A B
AB
D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use; D003521:Cyclopropanes; D005260:Female; D010049:Ovarian Diseases / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D018384:Oxidative Stress / Q000187:drug effects / Q000502:physiology; D020011:Protective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D011804:Quinolines / Q000494:pharmacology / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D015427:Reperfusion Injury / Q000378:metabolism / Q000473:pathology* / Q000517:prevention & control*; D013440:Sulfides
D000085:Acetates; D000975:Antioxidants; D003521:Cyclopropanes; D020011:Protective Agents; D011804:Quinolines; D013440:Sulfides; C093875:montelukast